Table 5.

Patient characteristics

Characteristic	No mutation, no.	CFH mutation, no.	MCP mutation, no.	IF mutation, no.	P1	P2	P3
Disease onset
Childhood, younger than 18 y	52 (86)	30 (42)	10 (14)	3 (6)	.22	.43	> .999
Adulthood, 18 y or older	34 (86)	12 (42)	4 (14)	3 (6)	.22	.43	> .999
Triggers
Pregnancy	6 (66)	1 (26)	0 (12)	2 (5)	.39	.28	.49
Drugs	4 (66)	1 (26)	0 (12)	None	.67	.38	.49
Flulike, gastroenteritis, other infections	46 (66)	18 (26)	12 (12)	3 (5)	.96	.03	.03
No triggers	1 (66)	1 (26)	0 (12)	None	NA	NA	NA
Other triggers	10 (66)	5 (26)	0 (12)	None	.63	.15	.10
Recurrences	30 (84)	15 (42)	9 (14)	2 (6)	> .999	.04	.06
Biochemical evaluation
Reduced C3 serum levels, 83 mg/dL or less*	22 (71)	16 (31)	4 (12)	3 (5)	.047	.87	.28
Reduced C4 serum levels, 15 mg/dL or less*	6 (69)	1 (29)	0 (12)	0 (4)	.36	.29	.51
Reduced CFH serum levels, 350 mg/L or less†	1 (73)	5 (34)	0 (12)	0 (5)	.005	.68	.16
Reduced IF serum levels, below 70%‡	0 (57)	0 (23)	0 (10)	0 (3)	NA	NA	NA

IF mutation group has not been included in statistical analysis. The numbers of patients for whom data were available are reported in parentheses. Significant P values are in italics.

P1 indicates no mutation versus CFH mutation; P2, no mutation versus MCP mutation; P3, CFH mutation versus MCP mutation; and NA, not applicable.

^*C3 and C4 levels were measured by kinetic nephelometry.

^†CFH serum levels were measured by radial immunodiffusion assay.

^‡IF serum levels were measured by ELISA.